Making Ingredients Smarter
PXL8 transforms complex liquid ingredients into high-performance, shelf-stable powders.
Using our proprietary technology platform, we encapsulate and enhance nature’s offerings, converting liquids into free-flowing, shelf-stable powders that are easier to store, ship, measure, and integrate across food, wellness, and pharmaceutical products.
Our powders are engineered for performance, offering precise control over ingredient behavior, including immediate-release (IR), extended-release (XR), and multi-phase delivery, along with flavor masking, color control, and extended shelf life.
PXL8 Powders are smarter, customizable, and built to scale.
PXL8 transforms liquid ingredients into stable, functional, and powerful powders.
Powders work better, yet present challenges
Many valuable ingredients start as liquids, but liquids are messy, unstable, and expensive to handle. Powders improve stability, consistency, and manufacturability, yet traditional powderization relies on heat, chemicals, water, or sugar-heavy fillers such as maltodextrin. Legacy processes degrade quality, increase waste, and impact health.
A Smarter Way to Powderize
PXL8’s ingredient platform technology uses a natural mineral base, with no heat, no solvents, no water, and no sugar.
Longer shelf life? Check.
Better absorption? Done.
Slashed production costs and environmental impacts? Absolutely.
We're not politely suggesting improvements to the ingredient industry—we're here to pixelate it into something better, cleaner, and genuinely fit for purpose.
Solution Built from Real-World Research
Founded in 2024, PXL8 is based on research by Dr. Monica Odell, Co-Founder and Chief Science Officer, who brings over 20 years of pharmaceutical formulation and drug-delivery experience.
After seeing the same challenges as a consultant, she set out to create a cleaner alternative.
Built to execute. Designed to scale.
PXL8’s leadership team combines pharmaceutical science, international business development, operations, and commercialization—with a foundation of trust and long-standing collaboration that significantly reduces execution risk for an early-stage company.
Our Team
Monica Odell, PhD
Dr. Odell brings over 20 years of pharmaceutical formulation and drug-delivery experience, including NIH-funded research and specialized expertise spanning R&D through commercial scale.
She leads R&D, IP strategy, and technical validation, translating pharmaceutical-grade precision into scalable solutions for consumer packaged goods.
Co-Founder & Chief Science Officer
Ben Odell
With 10 years of experience in natural products, Ben brings expertise in FDA-compliant product development, operational leadership, and brand strategy.
His background in cybersecurity informs PXL8’s technology-forward mindset, while his use of AI tools drives efficiency across product development, operations, and go-to-market execution.
Co-Founder & Chief Innovation Officer
Matthew Moden
Matthew is a serial entrepreneur with two successful exits and a board member of the Independent British Vape Association.
As Chief Executive Officer, he leads business development, international expansion, and investor relations, ensuring PXL8’s technical innovation is matched with disciplined commercial execution and global market strategy.
Chief Executive Officer
Jameson MacDonnell
Jameson brings 15+ years of experience in healthcare commercialization, business development, operations, and growth strategy. After first serving as an advisor, he joined PXL8 full-time as Chief Operating Officer.
He leads financial strategy, capital funding initiatives, partnerships, and execution.
Chief Operating Officer
Dan Miller, PhD
Dr. Miller is a pharmaceutical formulation expert with decades of experience, multiple patents, and deep specialization in industrial-scale processes.
A long-time mentor to Dr. Odell, he personally invested significant resources to validate PXL8’s technology and continues to advise on IP development, scale-up, and technical risk reduction.
Science Advisor